U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Maine Natural Health, Inc. - 525870 - 10/01/2019
  1. Warning Letters

CLOSEOUT LETTER

Maine Natural Health, Inc. MARCS-CMS 525870 —

Delivery Method:
United Parcel Service
Product:
Dietary Supplements
Recipient:
Recipient Name
Patricia Leighton
Recipient Title
CEO
Maine Natural Health, Inc.

825 Atlantic Hwy
Warren, ME 04864-4617
United States

Issuing Office:
Division of Human and Animal Food Operations East I (HAFE1)

158-15 Liberty Avenue
Jamaica, NY 11433
United States

Dear Ms. Leighton:

The Food and Drug Administration has completed an evaluation of your firm's corrective actions in response to our Warning Letter CMS# 525870, issued on December 19, 2017. Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/
CDR Catherine Beer
Director, Compliance Branch
Office of Human and Animal Food Operations East Division 1

Back to Top